Trial reportMolecular imaging and biology2013
Whole body biodistribution and radiation dosimetry in humans of a new PET ligand, [(18)F]-FEPPA, to image translocator protein (18 kDa).
Trial report in Molecular imaging and biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- First human whole-body biodistribution and dosimetry analysis of [European journal of nuclear medicine and molecular imaging · 2026Article
- Abbreviated dynamic total-body [Quantitative imaging in medicine and surgery · 2025Article
- Effects of Cigarette Smoking and 3-Day Smoking Abstinence on Translocator Protein 18 kDa Availability: A [Addiction biology · 2025Observational
- Total-body dynamic PET/CT imaging reveals kinetic distribution of [European journal of nuclear medicine and molecular imaging · 2024Article
- Dynamic total-body PET/CT imaging with reduced acquisition time shows acceptable performance in quantification of [European journal of nuclear medicine and molecular imaging · 2024Article
- A first-in-man study of [Annals of nuclear medicine · 2024Article
- Neuroinflammation in Low-Level PM2.5-Exposed Rats Illustrated by PET via an Improved Automated Produced [Molecular imaging · 2022Article
- Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.Frontiers in medicine · 2022Review
- GMP-compliant fully automated radiosynthesis of [EJNMMI research · 2021Article
- Plasma radio-metabolite analysis of PET tracers for dynamic PET imaging: TLC and autoradiography.EJNMMI research · 2020Article
- [EJNMMI research · 2020Article
- Imaging adipose tissue browning using the TSPO-18kDa tracer [Molecular metabolism · 2019Article
- Radiation dosimetry of [EJNMMI research · 2019Article
- An Optimized MicroPET Imaging Method for the Distribution and Synergies of Natural Products.Frontiers in pharmacology · 2018Article
- Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.Current medicinal chemistry · 2016Review
- Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [(18)F]UCB-H: First-in-Human Study.Molecular imaging and biology · 2015Article
- Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging.Journal of neuroinflammation · 2015Review
- Influence of TSPO genotype on 11C-PBR28 standardized uptake values.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose[(18)F]-FEPPA is a translocator protein (18 kDa, TSPO) positron emission tomography (PET) radiotracer. Radiation dosimetry was estimated from the whole body biodistribution, taking into consideration TSPO rs6971 (Ala147Thr) polymorphism. PROCEDURES: [(18)F]-FEPPA whole body PET scans were acquired for six healthy subjects. Time-activity curves were generated from regions of interest of nine organs, from which normalized accumulated activities were calculated and thus internal dose, using OLINDA/EXM 1.1. Genotyping of rs6971, associated with high- and low-affinity [(18)F]-FEPPA binding (high-affinity binder (HAB) and low-affinity binder (LAB)), was performed.
resultsFive subjects exhibited the C/C (HAB) allele, and the other carried the minor allele T/T (LAB). The LAB whole body biodistribution showed highest radioactivity accumulation in bladder, whereas in HABs, the spleen received the highest dose. The effective dose of the single LAB (16.3 μSv/MBq) was 23 % less than the mean of the HABs (21.0 ± 2.9 μSv/MBq). When including all subjects, the effective dose was 20.2 ± 3.0 μSv/MBq.
conclusions[(18)F]-FEPPA radiation dose is consistent with other (18)F-labeled radioligands and the Ala147Thr genotype agreed with [(18)F]-FEPPA distribution.
Indexed as
Identifiers
22895910What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.